SCHEDULE: AIGH Capital Management Updates Stake in Theratechnologies, Holding 3.4% of Common Stock

AIGH Capital Management LLC and Orin Hirschman have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 3.4% of Theratechnologies, Inc.'s common stock as of June 30, 2025.

Summary

• AIGH Capital Management LLC, AIGH Investment Partners, L.L.C., and Orin Hirschman (collectively, the "Reporting Persons") have filed Amendment No. 3 to their Schedule 13G.
• The filing reports beneficial ownership of 2,082,491 shares of Theratechnologies, Inc. Common Stock.
• This represents 3.4% of the total class of securities.
• Orin Hirschman and AIGH Capital Management LLC each hold sole voting and sole dispositive power over all 2,082,491 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, providing neutral information without positive or negative operational implications for the company.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm in a biotechnology company. It reflects an investment position rather than operational or strategic insights into Theratechnologies, Inc. or the broader industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake in the company, indicating continued investment by AIGH Capital Management.

Next Steps

• The Reporting Persons will file future amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if their intent regarding the investment changes.

Key Dates

Keywords

Theratechnologies Inc., AIGH Capital Management, Orin Hirschman, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology, Pharmaceuticals